Inhaled adenoviral gene therapy of a phosphorylation deficient-Survivin mutant, with dominant-negative properties, reversed MCT-induced PAH and prolonged the survival by 25% in animal models [154]. The gene discussed is BIRC5; the disease is pulmonary arterial hypertension.